Nimulid Strong Announces Partnership with Patna Pirates as Official Pain Relief Partner for Pro Kabaddi League Season 12

Mankind Pharma’s flagship brand Nimulid Strong, the neck pain specialist, has announced its association with Patna Pirates as the Official Pain Relief Partner for Pro Kabaddi League Season 12. This strategic partnership brings together the power-packed pain relief solution and one of kabaddi’s most formidable teams, celebrating India’s indigenous sport with the brand’s signature ‘Dugna Dum’ philosophy.

The topical pain relief market in India is valued at more than ₹5,000 crore, with most brands offering 1.16% diclofenac concentration. Nimulid Strong, formulated with 2X Diclofenac at 2.32% concentration, delivers targeted relief that matches the intensity and demands of kabaddi – a sport where players endure sudden pulls, rapid twists, and bone-strong tackles that put immense strain on the neck and body.

“Born in India, Nimulid Strong takes pride in supporting the games that are truly our own. Kabaddi is more than a sport; it’s part of our soil and spirit, and as an Indian brand, it’s our duty and honour to stand behind it with Dugna Dum,” said Mr. Joy Chatterjee, Vice President, Sales and Marketing Head, Consumer Business Unit, Mankind Pharma “The Patna Pirates embody the same unbreakable resilience and fighting spirit that Nimulid Strong represents. Just as kabaddi heroes rise after every fall, our brand salutes the everyday warriors who push through pain with determination.”

The partnership strategically aligns with kabaddi’s physical demands, particularly the neck strain that players experience during raids and tackles. Nimulid Strong’s rapid action formula starts working in just 2 minutes, making it the perfect ally for athletes who need instant, powerful relief to stay battle-ready.

“Kabaddi pushes players to their physical limits, where every raid and tackle demands Dugna Dum and brings real, unforgiving pain. Nimulid Strong steps into this very arena, ready to deliver instant, powerful relief with Do Guna Diclofenac,” Mr. Chatterjee added. “We’re backing the team’s speed and strength, helping them recover faster and maintain their competitive edge.“

As the first major launch of the year for Mankind Pharma in the topical pain relief category, Nimulid Strong has demonstrated exceptional market performance. The brand has sold approximately 20 lakh gel units and 10 lakh spray units in its first year, according to IQVIA Market Study Data.

Nimulid Strong is available in two powerful formats designed for different lifestyle needs:

• Nimulid Strong Gel: A deep-action formula for long-lasting relief with deep-penetrating action
• Nimulid Strong Spray: Hassle-free, on-the-go application perfect for active individuals

The products are specially formulated to target neck pain, offering quick, localised relief from pain, stiffness, and inflammation. Mankind Pharma plans to further disrupt the category with innovative formats including balms, roll-ons, and tablets in the near future.

About Mankind Pharma 

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of Bharat Serums and Vaccines Limited, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind’s distribution network includes a robust field force of 17,700+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 30 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 730 scientists. 

For more information, visit www.mankindpharma.com or contact:

Natasha Raj – 9205057627 – natasha.raj@mankindpharma.com 

Apoorva Sharma – 9999739452 – apoorva.sharma@adfactorspr.com